Contract Title: A hapten based multiplexed assay for HER2/neu, ER, and PR in breast cancer tumors
Contract Research Summary:
Breast cancer cell expression of the HER2/neu growth factor receptor, the estrogen receptor, and the progesterone receptor can indicate malignancy and predict response to therapy. In this contract research, we developed a high content screen for these biomarkers using haptens (molecular tags that conjugate primary antibodies to secondary antibodies or other reagents) to enable simultaneous cell-by-cell quantification of all three biomarkers, cytokeratin staining, and nuclear ploidy. We also developed methods for hematoxylin/eosin staining for tissue morphology from the same tissue sections. We improved CyteSeer® automated nuclear recognition algorithms to segment crowded nuclei in breast cancer tissue sections. We validated our assay using a tissue micro array of eight reference breast cancer cell lines and samples from 75 patients, and our results had high concordance with conventional pathology phenotyping. Our assay can improve the throughput and accuracy of clinical breast cancer diagnosis.
Funding Agency: NIH/National Cancer Institute
Contract Period: September 2010 – September 2013